Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sorting nexin-2 is a member of the sorting nexin family, characterized by a phox (PX) domain that binds phosphoinositides, and sometimes also a BAR (Bin/Amphiphysin/Rvs) domain[2][3][4]. SNX2 is involved in intracellular protein sorting, especially within early endosomes, where it helps regulate endosomal sorting and possibly trafficking of internalized cell surface receptors such as the epidermal growth factor receptor (EGFR) to lysosomes for degradation[2][3]. Although SNX2 can bind to certain phosphoinositide species and interacts with other sorting nexins, in mammalian cells it appears to play a non-essential or minor, possibly modulatory, role in endosome-to-Golgi protein retrieval[3]. Loss of SNX2 affects protein sorting and organelle homeostasis, potentially contributing to oncogenic transformation, but current evidence does not identify it as a principal drug target or direct therapeutic receptor[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sorting nexin-2 (SNX2).